Immune Therapeutics, Inc. (OTCMKTS:IMUN) Files An 8-K Regulation FD DisclosureItem 7.01. Regulation FD Disclosure.
On November 30, 2017, Immune Therapeutics, Inc. (the “Company”) issued a letter to update its shareholders on the Company’s recent progress and its objectives for 2018. A copy of a press release containing the letter is filed as Exhibit 99.1 hereto.
The information in this current report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits. The following exhibits are filed herewith.
|
Exhibit No. |
Description |
| 99.1 | Letter to Shareholders |
Immune Therapeutics, Inc. ExhibitEX-99.1 2 ex99-1.htm Immune Therapeutics,…To view the full exhibit click here
About Immune Therapeutics, Inc. (OTCMKTS:IMUN)
Immune Therapeutics, Inc. is a biotechnology company. The Company is involved in the manufacturing, distribution and marketing of therapies to combat chronic, life-threatening diseases through the activation and modulation of the body’s immune system using its patented immunotherapy. The Company’s products and immunotherapy technologies are designed to improve the treatment of cancer, infections, such as human immunodeficiency virus (HIV)/acquired immuno deficiency syndrome (AIDS), chronic inflammatory diseases and autoimmune diseases. Its technology platform is built on various immunotherapies, such as Low Dose Naltrexone (LDN) and Methionine-Enkephalin (MENK). Its technology offers treatment for a range of cancers. The Company’s clinical programs involve immunotherapy with Methionine-Enkephalin (MENK) (sometimes referred to as opioid growth factor) and its Low Dose Naltrexone (LDN) product or LodonalTM, which stimulates the immune system even in patients with advanced cancer.
